Xiaohua Wang

Dr. Xiaohua Wang


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2025 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
GWGang Wang
Gang Wang
XZXueyuan Zhou
Xueyuan Zhou
XPXiaoyan Pang
Xiaoyan Pang
KMKe Ma
Ke Ma
LLLu Li
Lu Li
XWXiaohua Wang
Xiaohua Wang
With the global population aging, the incidence of neurodegenerative diseases (NDs), such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis, has been progressively increasing. However, effective therapeutic strategies and clinical drugs for these disorders remain scarce. Curcumin, a natural polyphenolic compound primarily derived from the herbaceous plant Curcuma longa L., has been proposed as a promising candidate for ND treatment based on the excellent antioxidant, anti-inflammatory and neuroprotective properties. Its pharmacological activities encompass scavenging reactive oxygen species, mitigating toxic protein aggregation and cytotoxicity, repairing mitochondrial dysfunction, and inhibiting excessive neuronal apoptosis. Compared with synthetic drugs, curcumin demonstrates a more favorable safety profile with fewer side effects. Nevertheless, its clinical application is substantially hindered by poor bioavailability, which stems from low aqueous solubility, inefficient intestinal absorption, and rapid metabolism and systemic elimination. Conventional administration methods often fail to achieve effective concentrations in vivo. Further clinical trials are also required to validate the therapeutic efficacy and potential adverse effects in human subjects. This article systematically reviews the pathogenesis of NDs and the knowledge on curcumin including pharmacological effects, neuroprotective mechanisms, functions across specific NDs and advanced strategies to enhance the bioavailability, with the aim of promoting the development and clinical translation of curcumin-based therapeutics for NDs.

Verified
Journal Article
Open access
PDF file
CTChengfang Tang
Chengfang Tang
LLLixin Li
Lixin Li
TCTing Chen
Ting Chen
LYLi Yulin
Li Yulin
BZBo Zhu
Bo Zhu
YHYonglan Huang
Yonglan Huang
The aim of this study was to observe the outcomes of newborn screening (NBS) in a certain population by using next-generation sequencing (NGS) as a first-tier screening test combined with tandem mass spectrometry (MS/MS). We performed a multicenter study of 29,601 newborns from eight screening centers with NBS via NGS combined with MS/MS. A custom-designed panel targeting the coding region of the 142 genes of 128 inborn errors of metabolism (IEMs) was applied as a first-tier screening test, and expanded NBS using MS/MS was executed simultaneously. In total, 52 genes associated with the 38 IEMs screened by MS/MS were analyzed. The NBS performance of these two methods was analyzed and compared respectively. A total of 23 IEMs were diagnosed via NGS combined with MS/MS. The incidence of IEMs was approximately 1 in 1287. Within separate statistical analyses, the positive predictive value (PPV) for MS/MS was 5.29%, and the sensitivity was 91.3%. However, for genetic screening alone, the PPV for NGS was 70.83%, with 73.91% sensitivity. The three most common IEMs were methylmalonic academia (MMA), primary carnitine deficiency (PCD) and phenylketonuria (PKU). The five genes with the most common carrier frequencies were PAH (1:42), PRODH (1:51), MMACHC (1:52), SLC25A13 (1:55) and SLC22A5 (1:63). Our study showed that NBS combined with NGS and MS/MS improves the performance of screening methods, optimizes the process, and provides accurate diagnoses.

29 May 2025 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
XZXueyuan Zhou
Xueyuan Zhou
RBRantong Bao
Rantong Bao
XGXin Guan
Xin Guan
WLWenzhuo Li
Wenzhuo Li
CYChenxin Yang
Chenxin Yang
XWXiaohua Wang
Xiaohua Wang
Background: Human papillomavirus (HPV) infection is the primary cause of cervical cancer, and HPV self-sampling has emerged as a novel screening method with the potential to increase screening coverage and early detection of cervical cancer. However, the implementation of HPV self-sampling in China faces several challenges, including sociocultural factors, economic burdens, and low feedback rates. This study will aim to improve the feedback rate of HPV self-sampling results through a Pay-It-Forward approach and explore its impact on HPV positivity rates and subsequent treatment compliance.Methods: This study employs a randomized controlled trial (RCT) design, enrolling women aged 24 and older who have not received the HPV vaccine and have not undergone HPV self-sampling or cervical cancer screening in the past 12 months. Participants will be randomly divided into a control group (free distribution of HPV self-sampling kits) and an intervention group (pay up front for HPV self-sampling). The prepayment amount is 20 RMB, which is fully refunded upon completion of the self-sampling and feedback of results. The primary outcome measure is the feedback rate of HPV self-sampling results. The study is conducted at maternal and child health care and family planning service centers in Hohhot, Inner Mongolia Autonomous Region, with an expected enrollment of 108 participants.Discussion: The Pay-It-Forward approach is expected to significantly improve the feedback rate of HPV self-sampling results by enhancing participants’ psychological commitment and sense of responsibility. Additionally, this strategy may positively affect HPV positivity rates and subsequent treatment compliance. The innovation of this study lies in the first application of the Pay-It-Forward method to HPV self-sampling and the comprehensive analysis of urban-rural differences. The results of this study will provide a scientific basis for improving women’s cervical health awareness and optimizing HPV self-sampling intervention strategies, thereby promoting the widespread application of HPV self-sampling in cervical cancer screening.Trial registration: This study registered at ClinicalTrials.gov (ChiCTR2500095770) on January 13, 2025.

8 December 2023 in BMC Medical Genomics
Verified
Journal Article
Open access
PDF file
JWJie Wang
Jie Wang
YWYihan Wu
Yihan Wu
HDHong Dong
Hong Dong
YJYunpeng Ji
Yunpeng Ji
LZLichun Zhang
Lichun Zhang
XWXiaohua Wang
Xiaohua Wang
Objective: Haploinsufficiency is widely accepted as the pathogenic mechanism of hereditary spastic paraplegias type 4 (SPG4). However, there are some cases that cannot be explained by reduced function of the spastin protein encoded by SPAST. The aim of this study was to identify the causative variant of SPG4 in a large Chinese family and explore its pathological mechanism. Materials and methods: A five-generation family with 49 members including nine affected (4 males and 5 females) and 40 unaffected individuals in Mongolian nationality was recruited. Whole exome sequencing was employed to investigate the genetic etiology. Western blotting and immunofluorescence were used to analyze the effects of the mutant proteins in vitro. Results: A novel frameshift variant NM_014946.4: c.483_484delinsC (p.Val162Leufs*2) was identified in SPAST from a pedigree with SPG4. The variant segregated with the disease in the family and thus determined as the disease-causing variant. The c.483_484delinsC variant produced two truncated mutants (mutant M1 and M87 isoforms). They accumulated to a higher level and presented increased stability than their wild-type counterparts and may lost the microtubule severing activity. Conclusion: SPAST mutations leading to premature stop codons do not always act through haploinsufficiency. The potential toxicity to the corticospinal tract caused by the intracellular accumulation of truncated spastin should be considered as the pathological mechanism of SPG4.

13 April 2026 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
NDNi Ding
Ni Ding
YCYunlong Chen
Yunlong Chen
XZXueyuan Zhou
Xueyuan Zhou
GWGang Wang
Gang Wang
JLJiaying Li
Jiaying Li
XWXiaohua Wang
Xiaohua Wang
Background: HPV self-sampling can increase cervical cancer screening coverage. To effectively implement this innovative screening method, it is crucial to gain an in-depth understanding of women’s acceptance and preferences regarding each stage of the HPV self-sampling intervention process. This study aims to identify the key attributes of HPV self-sampling that drive acceptance among under-screened populations, thereby informing the development of equitable screening strategies that reduce barriers and expand access to cervical cancer prevention. Methods: In this cross-sectional study, we conducted a Discrete Choice Experiment (DCE) between 1 September 2024 and 31 March 2025, assessing preferences for five attributes of HPV self-sampling: accuracy, procedural difficulty, comfort, sampling time, and price. Analyses employed a mixed logit model, adhering to the Discrete Choice Experiment Reporting Checklist (DIRECT) reporting guideline. We estimated relative importance (RI) for each attribute, derived willingness-to-pay (WTP), and examined preference heterogeneity using interaction terms. Results: Of 200 valid responses, accuracy carried the greatest weight (RI 42.55%), followed by price (20.67%), sampling time (13.66%), procedural difficulty (11.68%), and comfort (11.45%). Low accuracy markedly reduced acceptance ( β = −6.640, p < 0.001), as did higher price ( β = −0.011, p < 0.001) and longer sampling time (>5 min; β = −1.703, p < 0.001). Participants showed a positive preference for more difficult procedures ( β = 1.550, p < 0.01), and moderate comfort increased acceptance ( β = 1.192, p < 0.001). Preference heterogeneity was observed: older age was associated with less aversion to low accuracy ( β = 0.190, p < 0.001), greater tolerance of procedural difficulty ( β = 0.106, p < 0.01), and a higher preference for moderate comfort ( β = 0.037, p < 0.05). Ethnic minorities were less averse to low accuracy than Han respondents ( β = 3.085, p < 0.01). Higher education was associated with a lower preference for moderate comfort ( β = −0.375, p < 0.05). Women already inclined towards self-sampling were more averse to low accuracy ( β = −2.623, p < 0.001) and procedural difficulty ( β = −1.095, p < 0.05). Conclusion: Accuracy, price, and sampling time are the dominant drivers of women’s choices for HPV self-sampling, and are simultaneously significantly moderated by individual characteristics such as age, ethnicity, education, and sampling preference. These findings underscore that effective screening programs must not only optimize core product attributes but also develop tailored strategies to address the distinct preferences of different demographic subgroups.

1 August 2021 in Journal of Zhejiang University (Medical Sciences)
Verified
Journal Article
Closed access
JWJie Wang
Jie Wang
BZBo Zhu
Bo Zhu
LZLichun Zhang
Lichun Zhang
YZYitong Zhao
Yitong Zhao
XWXiaohua Wang
Xiaohua Wang
YJYueqi Jia
Yueqi Jia
目的:评价苯丙氨酸羟化酶(PAH)基因c.158G>A(p.Arg53His)突变的临床意义。 方法:持续监测2名PAH基因携带p.Arg53His突变的疑似高苯丙氨酸血症患儿血液中苯丙氨酸(Phe)浓度,分析PAH蛋白的跨种属保守性,应用Swiss-Model对正常结构及变异结构的PAH进行蛋白质三维结构建模及比对分析突变所致蛋白质空间结构的改变,检索现有数据库及文献统计p.Arg53His突变的人群携带率,应用等位基因基因表型值(APV)与基因型表型值(GPV)预测系统对该突变相关表型进行预测。结果:2例新生儿在PAH基因上分别检出两个突变:c.611A>G(p.Tyr204Cys)、c.158G>A(p.Arg53His)和c.1238G>C(p.Arg413Pro)、c.158G>A(p.Arg53His)。2例新生儿能耐受正常饮食,在随访期间血Phe水平在正常范围内。病例2的母亲为p.Arg53His纯合突变,长期未进行低蛋白质、低苯丙氨酸饮食干预,血Phe浓度、Phe/酪氨酸比值均在正常范围。突变的氨基酸在13个不同物种间并非高度保守。三维结构建模结果显示,p.Arg53His突变使得PAH第53位和第49位氨基酸之间的氢键由2个减少为1个,降低了二聚体的稳定性。p.Arg53His在高苯丙氨酸血症患者中的等位基因频率为0.01508,在健康人群中的等位基因频率为0.001621,其中东亚人群中的携带率最高,为0.01373。APV与GPV系统预测结果显示,该突变与轻度HPA型别相关。结论:PAH基因p.Arg53His突变与不同突变组合为复合杂合状态,可引起临床表型差异。p.Arg53His突变引起体内酶活性的降低不足以出现苯丙酮尿症疾病症状,为“可能良性变异”。